
GSK extends oncology push with Nuvalent acquisition

GSK plc has announced its largest acquisition in more than a decade with an agreement to buy U.S. cancer drug developer Nuvalent Inc for US$10.6 billion (A%15.1 billion). The British pharmaceutical giant said the all-cash transaction valued Boston-based Nuvalent at $124 per share, representing a 40% premium to the last closing price. Chief Executive Luke Miels said the acquisition was consis














